Abstract
A number of newly developed antiepileptic drugs are currently in use, among them Lamotrigine (LTG) is more common. Despite the extensive use of this drug, it has not been possible to predict the side effects especially the hepatotoxic reactions after long-term treatment. The present study was designed to find out alterations in the activities of liver enzymes after chronic exposure of rats to different dose of LTG. Adults male (Wistar) rats were treated orally with LTG [5 mg/kg body weight or 25 mg/kg body wt.] for 60 days. After the experimental period, auto analyzer carried out liver function tests. The liver histopathology was obtained after scarifying the rats. There was a significant increase in the level of ALP, AST, ALT and bilirubin at therapeutic dose of LTG. The increase level of these enzymes and bilirubin at toxic dose were much higher and significant. However, the total protein and albumin significantly decreased at toxic dose of LTG. Elevation of liver enzymes and bilirubin after chronic exposure of rats to high dose of LTG reflects hepatocellular damage that may lead to hepatitis. It is concluded that regular liver function and drug monitoring should follow the treatment with LTG.
Key words: Antiepileptic, Lamotrigine, and Liver function, Hepatitis
Full Text
The Full Text of this article is available as a PDF (86.5 KB).
References
- 1.Leppik I.E. Antiepileptic drugs in development: prospects for the near future. Epilepsia. 1994;35(suppl 4):29–40. doi: 10.1111/j.1528-1157.1994.tb05953.x. [DOI] [PubMed] [Google Scholar]
- 2.Leach M., Harden C.M., Millar A.A. Pharmacologicl studies of lamotrigine, a novel potential antiepileptic drug, II: Neurochemical studies on the mechanisms of action. Epilepsia. 1986;27:490–497. doi: 10.1111/j.1528-1157.1986.tb03573.x. [DOI] [PubMed] [Google Scholar]
- 3.Overstreet K., Costanza C., Behling C., Hassanin T., Masliah E. Fatal progressive hepatic necrosis associated with lamotrigine treatment: A case report and literature review. Dig. Dis. Sci. 2002;47:1921–1925. doi: 10.1023/A:1019627618972. [DOI] [PubMed] [Google Scholar]
- 4.Meshkibaf M.H., Subhash M.N., Rama, Rao B.S.S., Narayanan C.P., Kailashnath K.M. Comparative effect of single and poly therapy on liver enzymes in epileptic patients under long term treatment. NIMHANS J. 1995;13:141–146. [Google Scholar]
- 5.Betts T., Goodwin G., Withers R.M., Yuen A.W. Human safety of lamotrigine. Epilepsia. 1991;32(suppl 2):17–21. doi: 10.1111/j.1528-1157.1991.tb05881.x. [DOI] [PubMed] [Google Scholar]
- 6.Beghi E., Dimascio R. Antiepileptic drug toxic definition and mechanism of action. Neurol. Sci. 1986;7:209–222. doi: 10.1007/BF02230884. [DOI] [PubMed] [Google Scholar]
- 7.Schmidt W. Adverse effects of antiepileptic drugs. New York: Raven Press; 1982. [Google Scholar]
- 8.Jeavons P.M. Hepatotoxicity of antiepileptic drugs. In: Oxley J, Janz D, Meinardi H., editors. Antiepileptic therapy: Chronic toxicity of antiepileptic drugs. New York: Raven Press; 1983. pp. 1–45. [Google Scholar]
- 9.Mullick F.G., Ishak K.G. Hepatic injury associated with diphenyl-hydantion therapy: A clinicopathological study of 20 cases. Am. J. Clin. Pathol. 1980;74:442–452. doi: 10.1093/ajcp/74.4.442. [DOI] [PubMed] [Google Scholar]
- 10.Levine B., Jufer R.A., Mialek J.E. Lamotrigine distribution in two postmortem cases. J. Anal. Toxicol. 2000;24:635–637. doi: 10.1093/jat/24.7.635. [DOI] [PubMed] [Google Scholar]
- 11.Fayad M., Choueiri R., Mikati M. Potential hepatotoxicity of lamotrigin. Pediatr Neurol. 2000;22:49–52. doi: 10.1016/S0887-8994(99)00106-X. [DOI] [PubMed] [Google Scholar]
- 12.Meldrum B.S. Lamotrigine a novel approach. Seizure. 1994;3(suppl A):41–45. [PubMed] [Google Scholar]
- 13.Oliveros-Juste A., Bertol V., Oliveros-Cid A., Sanchez-Marin B., Alarcia R. Therapeutic benefits of monotherapy with Lamotrigine. Rev. Neurol. 1999;29:1277–1284. [PubMed] [Google Scholar]